NL8901159A - Toepassing van gonadoliberinederivaten voor de bereiding van tumor-remmende farmaceutische preparaten. - Google Patents

Toepassing van gonadoliberinederivaten voor de bereiding van tumor-remmende farmaceutische preparaten. Download PDF

Info

Publication number: NL8901159A
Authority: NL; Netherlands
Prior art keywords: gnrh; group; general formula; preparation; tumors
Prior art date: 1988-05-10

Application number

NL8901159A

Other languages

English (en)

Dutch (nl)

Original Assignee

Innofinance Altalanos Innovaci

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-10

Filing date

1989-05-09

Publication date

1989-12-01

1989-05-09 Application filed by Innofinance Altalanos Innovaci filed Critical Innofinance Altalanos Innovaci

1989-12-01 Publication of NL8901159A publication Critical patent/NL8901159A/nl

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 13
238000002360 preparation method Methods 0.000 title claims description 12
230000001875 tumorinhibitory effect Effects 0.000 title 1
206010028980 Neoplasm Diseases 0.000 claims description 26
238000011282 treatment Methods 0.000 claims description 19
229940088597 hormone Drugs 0.000 claims description 17
239000005556 hormone Substances 0.000 claims description 17
238000000034 method Methods 0.000 claims description 17
230000001419 dependent effect Effects 0.000 claims description 11
108050000048 Gonadoliberin Proteins 0.000 claims description 8
102000009165 Gonadoliberin Human genes 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 7
230000003054 hormonal effect Effects 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 5
150000008575 L-amino acids Chemical group 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 3
239000002184 metal Chemical class 0.000 claims description 3
229910052751 metal Chemical class 0.000 claims description 3
150000008574 D-amino acids Chemical group 0.000 claims description 2
125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
150000004696 coordination complex Chemical class 0.000 claims description 2
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 2
125000001982 tryptophyl group Chemical group 0.000 claims description 2
239000002434 gonadorelin derivative Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 32
102000009151 Luteinizing Hormone Human genes 0.000 description 16
108010073521 Luteinizing Hormone Proteins 0.000 description 16
229940040129 luteinizing hormone Drugs 0.000 description 16
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 13
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 13
229940028334 follicle stimulating hormone Drugs 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
230000000694 effects Effects 0.000 description 12
230000002611 ovarian Effects 0.000 description 12
208000026310 Breast neoplasm Diseases 0.000 description 11
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 11
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 11
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 11
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 11
206010006187 Breast cancer Diseases 0.000 description 10
230000007423 decrease Effects 0.000 description 10
230000006870 function Effects 0.000 description 10
230000016087 ovulation Effects 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 8
238000000586 desensitisation Methods 0.000 description 7
150000003431 steroids Chemical class 0.000 description 7
241000251468 Actinopterygii Species 0.000 description 6
230000000259 anti-tumor effect Effects 0.000 description 6
235000019688 fish Nutrition 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
229960003387 progesterone Drugs 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
NMJREATYWWNIKX-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NMJREATYWWNIKX-XJIZABAQSA-N 0.000 description 5
WPKQYFUSPONRAT-BXXNOCLASA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-5-amino-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hy Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 WPKQYFUSPONRAT-BXXNOCLASA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
230000009471 action Effects 0.000 description 5
230000003325 follicular Effects 0.000 description 5
230000002710 gonadal effect Effects 0.000 description 5
230000035800 maturation Effects 0.000 description 5
230000010534 mechanism of action Effects 0.000 description 5
230000001817 pituitary effect Effects 0.000 description 5
239000000186 progesterone Substances 0.000 description 5
230000001568 sexual effect Effects 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
102000006771 Gonadotropins Human genes 0.000 description 4
108010086677 Gonadotropins Proteins 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229960005309 estradiol Drugs 0.000 description 4
229930182833 estradiol Natural products 0.000 description 4
210000002149 gonad Anatomy 0.000 description 4
239000002622 gonadotropin Substances 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
230000009467 reduction Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
229940094892 gonadotropins Drugs 0.000 description 3
230000012010 growth Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
241000894007 species Species 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
108010069236 Goserelin Proteins 0.000 description 2
101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
102100033467 L-selectin Human genes 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
230000010009 steroidogenesis Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
-1 GnRH ethylamide analog Chemical class 0.000 description 1
102000008238 LHRH Receptors Human genes 0.000 description 1
108010021290 LHRH Receptors Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000005002 female reproductive tract Anatomy 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
125000001998 leucyl group Chemical group 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003578 releasing effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000035938 sexual maturation Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

NL8901159A 1988-05-10 1989-05-09 Toepassing van gonadoliberinederivaten voor de bereiding van tumor-remmende farmaceutische preparaten. NL8901159A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU234788		1988-05-10
HU882347A HU199694B (en)	1988-05-10	1988-05-10	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives

Publications (1)

Publication Number	Publication Date
NL8901159A true NL8901159A (nl)	1989-12-01

Family

ID=10958948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8901159A NL8901159A (nl)	1988-05-10	1989-05-09	Toepassing van gonadoliberinederivaten voor de bereiding van tumor-remmende farmaceutische preparaten.

Country Status (16)

Country	Link
JP (1)	JPH0215097A (fr)
KR (1)	KR900017610A (fr)
BE (1)	BE1004932A3 (fr)
CH (1)	CH678013A5 (fr)
DE (1)	DE3915317A1 (fr)
DK (1)	DK228289A (fr)
FI (1)	FI892275A7 (fr)
FR (1)	FR2631237A1 (fr)
GB (1)	GB2218335B (fr)
GR (1)	GR890100315A (fr)
HU (1)	HU199694B (fr)
IL (1)	IL89998A0 (fr)
IT (1)	IT1229251B (fr)
LU (1)	LU87516A1 (fr)
NL (1)	NL8901159A (fr)
SE (1)	SE8901660L (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4410514A (en) *	1982-12-06	1983-10-18	The Salk Institute For Biological Studies	GnRH Agonists
IT1178775B (it) *	1983-12-23	1987-09-16	Konzponti Valto Es Hitelbank R	Derivati della gonadoliberina e procedimento per la loro preparazione
HU189394B (en) *	1983-12-23	1986-06-30	Koezponti Valto- Es Hitelbank Rt Innovacios Alap,Hu	Method for producing spermatozoa suitable for fertilization from mature fishes
US4760053A (en) *	1984-08-02	1988-07-26	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers
DE3586053D1 (de) *	1984-08-02	1992-06-17	Labrie	Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
HU193607B (en) *	1985-07-18	1987-11-30	Innofinance Altalanos Innovaci	Process for production of sexual products applyable for natural or artificial insemination for mammates
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
HU194913B (en) *	1986-01-03	1988-03-28	Innofinance Altalanos Innovaci	Process for producing novel gonadoliberin derivatives containing in the sixth position aromatic amino carboxylic acid and medical preparations containing these compounds

1988
- 1988-05-10 HU HU882347A patent/HU199694B/hu active IP Right Revival
1989
- 1989-04-18 IL IL89998A patent/IL89998A0/xx unknown
- 1989-05-08 CH CH1725/89A patent/CH678013A5/de not_active IP Right Cessation
- 1989-05-09 NL NL8901159A patent/NL8901159A/nl not_active Application Discontinuation
- 1989-05-10 DK DK228289A patent/DK228289A/da not_active Application Discontinuation
- 1989-05-10 DE DE3915317A patent/DE3915317A1/de not_active Withdrawn
- 1989-05-10 FI FI892275A patent/FI892275A7/fi not_active Application Discontinuation
- 1989-05-10 KR KR1019890006230A patent/KR900017610A/ko not_active Withdrawn
- 1989-05-10 LU LU87516A patent/LU87516A1/fr unknown
- 1989-05-10 JP JP1115265A patent/JPH0215097A/ja active Pending
- 1989-05-10 GR GR890100315A patent/GR890100315A/el unknown
- 1989-05-10 FR FR8906094A patent/FR2631237A1/fr active Pending
- 1989-05-10 SE SE8901660A patent/SE8901660L/ not_active Application Discontinuation
- 1989-05-10 BE BE8900499A patent/BE1004932A3/fr not_active IP Right Cessation
- 1989-05-10 GB GB8910724A patent/GB2218335B/en not_active Expired - Fee Related
- 1989-05-11 IT IT8920435A patent/IT1229251B/it active

Also Published As

Publication number	Publication date
HU199694B (en)	1990-03-28
IT1229251B (it)	1991-07-26
GR890100315A (el)	1990-03-12
HUT49813A (en)	1989-11-28
CH678013A5 (fr)	1991-07-31
DK228289A (da)	1989-11-11
GB2218335A (en)	1989-11-15
BE1004932A3 (fr)	1993-03-02
IL89998A0 (en)	1989-12-15
SE8901660D0 (sv)	1989-05-10
JPH0215097A (ja)	1990-01-18
DE3915317A1 (de)	1989-11-23
FI892275A7 (fi)	1989-11-11
DK228289D0 (da)	1989-05-10
FI892275A0 (fi)	1989-05-10
FR2631237A1 (fr)	1989-11-17
LU87516A1 (fr)	1990-12-11
SE8901660L (sv)	1989-11-11
GB8910724D0 (en)	1989-06-28
GB2218335B (en)	1991-09-25
KR900017610A (ko)	1990-12-19
IT8920435A0 (it)	1989-05-11

Legal Events

Date	Code	Title	Description
1995-01-02	BV	The patent application has lapsed

Publication	Publication Date	Title
Hsueh et al.	1981	Extrapituitary actions of gonadotropin-releasing hormone
Reissmann et al.	2000	The LHRH antagonist cetrorelix: a review
Breton et al.	1998	GTH I and GTH II secretion profiles during the reproductive cycle in female rainbow trout: relationship with pituitary responsiveness to GnRH-A stimulation
De Leeuw et al.	1987	The regulation of gonadotropin release by neurohormones and gonadal steroids in the African catfish, Clarias gariepinus
JPH06507604A (ja)	1994-09-01	黄体形成ホルモン放出ホルモン拮抗ペプチド
Tannenbaum et al.	1992	Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin.
Schally et al.	1987	Protective effects of analogs of luteinizing hormone-releasing hormone against x-radiation-induced testicular damage in rats.
Moszkowska et al.	1971	The influence of the pineal body on the gonadotropic function of the hypophysis
Collu et al.	1971	Blockade of ovulation by melatonin
Chodak	1989	Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma
Zalatnai et al.	1988	Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D‐Trp‐6‐LH‐RH
Ahluwalia et al.	1970	Effects of exogenous hormones on the male reproductive organs of vitamin A-deficient rats
Peterson et al.	1990	A long-acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse
ADAMS et al.	1986	Suppression of Plasma Gonadotropins and Testosterone in Adult Male Monke (Macaca fascicularis) by a Potent Inhibitory Analog of Gonadotropin-Releasing Hormone
NL8901159A (nl)	1989-12-01	Toepassing van gonadoliberinederivaten voor de bereiding van tumor-remmende farmaceutische preparaten.
Korkut et al.	1991	Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
Fink	1986	The endocrine control of ovulation
Reissmann et al.	1992	Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone
Reissmann et al.	1996	Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone
WO2002039995A2 (fr)	2002-05-23	Traitement combine de maladies dependantes des oestrogenes
Tominaga et al.	1990	Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats
KR100652457B1 (ko)	2006-11-30	엘에이치-알에이치 유사 화합물의 경구 투여용 알파-사이클로덱스트린 기재 약학적 조성물
KR100210472B1 (ko)	1999-07-15	황체형성 호르몬 분비 호르몬 길항 펩티드
Forti	1988	Clinicai applications of GnRH analogs
Engel et al.	2002	Cetrorelix, a potent LHRH-antagonist: Chemistry, pharmacology and clinical data